Podcasts about bionic pancreas

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, November 16, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Alcon stocks dipped on Wednesday as it released its Q3 earnings. Fast Five hosts Sean Whooley and Danielle Kirsh talk about the financial highlights of the quarter and the company's expectations for the full-year upon these results.  Ethicon has unveiled a hemostatic sealing patch in Europe. Whooley explains the technology behind the patch and the company's plans for a launch in the future.  Virtuoso Surgical won an NIH funding grant to support its surgical robot. Hear what the surgical robot does and what the company wants to do with the funding grant.  NeuroOne named a former Cardiovascular System VP as its new COO. The Fast Five hosts discuss who is taking over in this role, their career history and the optimism they bring to the company.  Beta Bionics won a pharmacy benefit for its bionic pancreas. Whooley talks about what the decision means for Beta Bionics and how it differs from the insurance benefits of insulin pumps.

Glucotrack is back in this news, this time with news of a former Medtronic veteran being tapped for its board director spot. Fast Five hosts Sean Whooley and Danielle Kirsh go over the new appointee and their career history. Zeiss Medical Technology this week announced it intends to unveil new ophthalmic innovations within its cataract and corneal refractive workflows. Find out what updates the company is planning to make and what executives are thinking. LivaNova has received FDA 510(k) clearance for its Essenz in-line blood monitor. Whooley talks about what the blood monitor does, how it helps patients and why this is an important innovation.  Beta Bionics closed a $100 million Series D funding round for its bionic pancreas. Tune in to discover what a bionic pancreas does and how optimistic executives are after this funding round. The field of surgical robotics is constantly innovating. Noah Medical this week announced positive first-in-human data for its own surgical robot. Learn more about the company's surgical robot, what the data said and how doctors feel about using the technology. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

In this month's episode of Dexcom's ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic's Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr Ed Damiano, Beta Bionic's founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you're using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out. Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide (https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. In this month's episode of Dexcom's ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic's Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr. Ed Damiano, Beta Bionic's founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr. Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you're using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom's partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users' glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Dr. Steven Russell MD, PhD is a Chief Medical Officer of Beta Bionics. About Hello Dexcom: https://provider.dexcom.com/prescribe-sample#block-contactus Dexcom Provider website: https://provider.dexcom.com/ About Beta Bionics: https://www.betabionics.com/ Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References: 1. Lynch J, Kanapka LG, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Calhoun P, Beck RW. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):726-736. doi: 10.1089/dia.2022.0341. PMID: 36173238; PMCID: PMC9529297. 2. Beck RW, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Calhoun P. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):681-696. doi: 10.1089/dia.2022.0167. PMID: 36173235; PMCID: PMC9529301. 3. Kruger D, Kass A, Lonier J, Pettus J, Raskin P, Salam M, Trikudanathan S, Zhou K, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Marak MC, Calhoun P, Beck RW. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):697-711. doi: 10.1089/dia.2022.0200. PMID: 36173236; PMCID: PMC9634987.

Ed Damiano is the Founder of Beta Bionics and he's here today to talk about the iLet Bionic Pancreas.  This BetterHelp link saves 10% on your first month of therapy Try delicious AG1 from Athletic Greens Use code JUICEBOX to save 35% at Cozy Earth  Get the Gvoke HypoPen CONTOUR NEXTONE smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH  Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey A full list of our sponsors  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The show is now available as an Alexa skill. My type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Follow Scott on Social Media @ArdensDay @JuiceboxPodcast Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on iTunes. Thank you! Arden's Day and The Juicebox Podcast are not charitable organizations.  

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Lilly becomes the first of the big three insulin makers to settle a class action lawsuit over pricing, the FDA approved Beta Bionics' iLet system, oral meds trialed for T2D seem to work as well as Ozempic injectable, Lego adds a T1D "friend" to their line and a big win for an American Ninja Warrior competitor with T1D. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by VIVI Cap Keeps your insulin at the exact right temperature, even in extreme heat or cold. XX Our top story, Eli Lilly has agreed to pay $13.5 million to end a six-year, class-action lawsuit accusing the company of overpriced its insulin. As part of the settlement, Lilly has agreed to cap out-of-pocket costs for its insulin at $35 per month for four years. That's three months after Lilly said it would cut insulin prices to that level. The lawsuit was filed in 2017, against insulin makers Lilly, Novo Nordisk and Sanofi. Plaintiffs claimed the companies joined in an “arms race” to raise list prices of their meds while the “real” price to pharmacy benefit managers remained constant or in some cases dipped. Price increases of insulins that previously cost $25 per prescription were pushed up to $450, the suit said. The increases, taken in “lockstep,” were “astounding and inexplicable,” according to the class action lawsuit. Novo and Sanofi have yet to settle this case. https://www.fiercepharma.com/pharma/eli-lilly-inks-settlement-long-running-insulin-pricing-lawsuit XX The FDA is changing its draft guidance for industry regarding Antidiabetic Drugs and Biological Products. It's been 15 years since an update. Topics covered in the draft guidance include: Hemoglobin A1c (A1C), a measure of average blood sugar, remaining an acceptable primary efficacy endpoint The FDA now considering a reduction in the risk of hypoglycemia (low blood sugar) to be a clinically relevant outcome measure for diabetes drug clinical trials, when accompanied by either a reduction or maintenance of an acceptable A1C. The use of data collected by continuous glucose monitoring (CGM) systems, which allow for nonstop, passive glucose monitoring, in clinical trials to potentially support hypoglycemia labeling claims. Recent advancements in CGM technology have led the agency to recognize the advantages of data collected from these systems in clinical drug development. The FDA will be accepting comments on the guidance until August 24, 2023. https://www.appliedclinicaltrialsonline.com/view/fda-on-track-to-updates-diabetes-efficacy-endpoints-guidance XX The iLet bionic pancreas from Beta Bionics gets FDA approval for people with type 1 age 6 and up. This is a unique system in that it starts with only the user's weight and requires meal announcements – no carb counting – to automate blood sugar. It will launch with the Dexcom G6 CGM. You'll hear from the company CEO this Tuesday in our next episode where we do a deep dive into the system. https://www.medicaldevice-network.com/news/beta-bionics-fda-insulin-pump/ XX Researchers had observed an increased incidence of type-1 diabetes cases during the COVID-19 pandemic. Now, a new study has confirmed the link and established a temporal association between the development of type-1 diabetes in children and infection with the SARS-CoV-2 virus. The new study published in Jama Network was the first research that used data, which indicated if the type-1 diagnosed children previously had COVID-19 infection. The researchers found the likelihood to develop type-1 diabetes increased by 57% in children who had a confirmed COVID-19 infection, compared to those who did not have the infection. https://www.medicaldaily.com/covid-19-infection-increases-incidence-type-1-diabetes-children-study-469854 XX New oral medication from Pfizer seems to stack up well next to Ozempic for weight loss. New study looked at people with type 2 found danuglipron when given twice a day, lowered blood sugar in patients at all doses and reduced body weight at the highest dose after 16 weeks. The weight loss with danuglipron is of a similar magnitude to that observed in the mid-stage data for Novo Nordisk's semaglutide, known as Ozempic when used for diabetes and Wegovy for obesity. The treatments, including Pfizer's danuglipron, belong to a class of drugs that mimic the gut hormone glucagon-like peptide-1 (GLP-1), which works by suppressing appetite and were initially developed to treat type 2 diabetes. Pfizer is also testing another oral diabetes drug, lotiglipron, which is given once daily and has said it plans to initiate late-stage development of only one of the two candidates. The company believes an oral therapy could appeal to patients who want to avoid injections. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-diabetes-drug-reduces-weight-similar-novos-ozempic-2023-05-22/ XX Artificial intelligence (AI) algorithms used to screen for and predict type 2 diabetes may be racially biased, which could perpetuate health disparities, according to a study published last week in PLOS Global Public Health. Risk prediction models for type 2 diabetes have shown promise in bolstering early detection and clinical decision-making, but the researchers pointed out that these models can bias the decision-making process if risk is miscalibrated across patient populations. The research team found that the Framingham Offspring Risk Score underestimated type 2 diabetes risk for non-Hispanic Black patients, but overestimated risk for their white counterparts. The ARIC Model and PRT overestimated risk for both groups, but to a greater extent for white patients. Research like this highlights that while data analytics and AI approaches may help find gaps in chronic disease management and care, racial disparities are still a major obstacle to achieving health equity for diabetes patients. A 2021 study of city-level data revealed significant disparities in diabetes mortality rates across the United States. The analysis sourced data from the 30 largest cities in the US and demonstrated that mortality rates were higher for Black individuals than for white individuals. Disparities were also found to be up to four times larger in some cities compared to others, with Washington, DC experiencing the highest rates of diabetes mortality inequities. https://healthitanalytics.com/news/potential-racial-bias-found-in-type-2-diabetes-risk-prediction-models XX 1 in 3 adults with Type 2 diabetes may have undetected cardiovascular disease. Elevated levels However, mildly elevated concentrations of of two protein biomarkers that indicate heart damage may be an early warning sign of changes in the structure and function of the heart, which may increase the risk for future heart failure, coronary heart disease or death. Researchers analyzed health information and blood samples for more than 10,300 adults collected as part of the U.S. National Health and Nutrition Examination Survey from 1999 to 2004. Study participants had reported no history of cardiovascular disease when they enrolled in the study. One-third (33.4%) of adults with Type 2 diabetes had signs of undetected cardiovascular disease, as indicated by elevated levels of the two protein markers, compared to only 16.1% of those without diabetes. https://medicalxpress.com/news/2023-05-adults-diabetes-undetected-cardiovascular-disease.html XX VIVI CAP XX MTV Documentary Films has acquired worldwide rights to Pay or Die, a film about Americans living with diabetes who face a cruel choice: pay the “extortionate” cost of insulin charged by pharmaceutical companies or risk death. Scott Alexander Ruderman and Rachael Dyer directed and produced the documentary, which premiered in March at SXSW. MTV Documentary Films plans a theatrical release later this year, followed by a debut on streaming platform Paramount+. Those personal stories in the film stretch across the country. “From a mother-and-daughter struggling to rebuild their lives after spending their rent money on insulin, to a young adult diagnosed with Type 1 diabetes during the COVID-19 pandemic, to a Minnesota family thrust into the national spotlight when their 26-year-old son dies from rationing his insulin, Pay or Die highlights this devastating struggle to survive while living with diabetes.” https://deadline.com/2023/05/pay-or-die-mtv-documentary-films-acquisition-directors-scott-alexander-ruderman-rachael-dyer-news-1235382566/ XX Katie Bone win the “American Ninja Warrior Women's Championship” — not only claiming the title but a cash prize of $50,000. She donated $5,000 to the Juvenile Diabetes Research Foundation and Pumped NM. Bone has not only appeared on three iterations of the competition series, but is also a nationally-ranked rock climber. While not the youngest competitor anymore, she was the shortest standing at 5 foot, 2 inches. She's been making waves since competing in “American Ninja Warrior Jr.” in 2020. To train for the event during the pandemic, her father built a ninja course in their backyard. During that competition, Bone, who was diagnosed with Type 1 diabetes at 11 years old, competed with both her insulin pump and glucose monitor on her arms. Being on the show also presents Bone with the opportunity to be an ambassador for Type 1 diabetes awareness and representation. Bone says Type 1 diabetes didn't end her life, it just changed it. “I hope I inspire a little kid to wear their pump on their arm,” Bone said. “It makes everything that you do that more amazing.” In February, Bone competed at the USA National Women's Team Climbing trials in Austin, Texas. During her fourth climb, she fell. “Katie heard four pops,” Tammy Bone said. “She tore her ACL and both sides of her meniscus. This was a moment she was preparing for all her life and it got put on pause.” Bone had surgery and has been getting physical therapy in Colorado. The family returned Monday night to New Mexico after being away for three months. Bone still has her eyes on the Olympics, though the road to recovery may take some more time. “I don't need easy, I just need possible,” she said. https://www.abqjournal.com/2602750/17-year-old-new-mexico-ninja-warrior-katie-bone-takes-the-title-in-womens-championship-competition.html XX Today LEGO has revealed the first wave of Friends sets for 2023, bringing in a new cast of characters and an update to the branding with a new logo. A new LEGO Friends television series will also accompany the new sets. LEGO's annual Play Well study revealed that 3 out of 4 children felt there were not enough toys with characters that represent them, so LEGO is aiming to bring more diverse representation to Heartlake City that's inclusive of not just various ethnicities and genders, but also disabilities and neurodivergence. LEGO says the 2023 sets and series will feature characters with limb difference, Downs Syndrome, anxiety, vitiligo, and even pets with disabilities, including a blind dog and a dog with a wheelchair. She has a CGM printed on her arm and even has a printed phone tile showing her blood sugar. Her name is Hannah and she's in 41744 Sports Center https://www.brothers-brick.com/2022/10/27/lego-friends-reveals-5-sets-for-2023-with-diverse-characters-to-better-represent-children-news/ XX XX On the podcast next week.. Beta Bionics CEO Sean Saint. Last week I MedT 780G That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

A new device can make things easier for patients with type 1 diabetes. Learn more about your ad choices. Visit megaphone.fm/adchoices

Get our free download! Implementing AMA Style – 8 Things to Get Right Join medical writer Dr. Emma Hitt Nichols as she relays information about the latest new FDA approvals from last week to help you stay updated. For clinicians, medical writers, medical science liasons, pharma sales reps, and other healthcare industry executives.  The FDA has approved the iLet Bionic Pancreas, which combines the iLet ACE Pump, iLet Dosing Decision Software, and a compatible continuous glucose monitor, providing an automated insulin delivery system for people with type 1 diabetes.   VYJUVEK, the first topical gene therapy, has received FDA approval for the treatment of dystrophic epidermolysis bullosa (DEB), a rare skin disease. It uses a nonreplicating HSV-1 vector to deliver the COL7A1 gene and restore skin structure.   EPKINLY has been approved as the first bispecific T cell engager (BiTE) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). MIEBO™, an ophthalmic solution, has been approved for the treatment of dry eye disease. It targets tear evaporation and is the first prescription drop specifically approved for DED.   The B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System has received FDA authorization to aid in the risk assessment of pregnant women with hypertensive disorders, including preeclampsia, a leading cause of maternal morbidity.   RINVOQ (upadacitinib) has been approved for adults with moderately to severely active Crohn's disease, providing an oral treatment option for patients who have had an inadequate response to tumor necrosis factor blockers.   Pfizer's RSVpreF vaccine candidate for respiratory syncytial virus (RSV) has received support for its efficacy and safety from the FDA's advisory committee. If approved, it could prevent RSV-related lower respiratory tract disease in infants.   The Connexus Direct Data Interface, a brain implant designated as a breakthrough device by the FDA, has the potential to help severely paralyzed patients regain communication abilities by deciphering neural signals.  Brought to you by Nascentmc.com. A group of MD- and PhD-level medical writers serving the continuing medical education industry and meeting medical writing deadlines with excellence and enthusiasm. 

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.

For CME Credit, click here: https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10092431   Presenter: Rabab Z. Jafri, MD Pediatric Endocrinologist Department of Pediatrics Texas Diabetes Institute UT Health San Antonio Overview: A Bionic Endocrine Pancreas for Automated Management of Glycemia in Diabetes Mellitus, grand rounds.  Plus, Pediatrics Now Host Holly Wayment gets reaction from Dr. Jafri about the bionic pancreas study published in NEJM, plus soundbites from patients in the clinical trial. Objectives: To increase awareness and education for pediatric providers   Financial Disclosures: Rabab Z. Jafri, MD has no financial relationships with ineligible companies to disclose.   The Pediatric Grand Rounds Planning Committee (Deepak Kamat MD, PhD, Daniel Ranch, MD and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose. Planning Committee member Steven Seidner, MD has disclosed he receives funding from Draeger Medical for the Clinical Study to Evaluate the Safety and Effectiveness of the Infinity Acute Care System Workstation Neonatal Care Babylog VN500 Device in High-Frequency Oscillatory Ventilation (HFOV) Mode in Extremely Low Birth Weight (ELBW) Neonates for which he is a co-principal investigator. Our wonderful pediatric endocrinology team sees patients at University Hospital's Texas Diabetes Institute. Credits: AMA PRA Category 1 Credits™ (1.00 hour) Non-Physician Participation Credit (1.00 hour) MOC-2 credit (1.00 hour) Target Audience: Pediatric Community Doctors and Providers Faculty, residents, health care providers; medical students and trainees.   Accreditation: The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.   Credit Designation: The UT Health Science Center San Antonio designates this live activity up to a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on applicability and acceptance, please consult your professional licensing board.  

Host: John Buse, MD, PhD Guest: Steven Russell, MD, PhD Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hospital.

A so-called bionic pancreas helped people across the age range manage their type 1 diabetes more easily, a recent study reports. Johns Hopkins diabetes expert Rita Kalyani says the device is much simpler to use than currently available insulin pumps. … Can a bionic pancreas improve management of type 1 diabetes? Elizabeth Tracey reports Read More »

Show Notes: A bionic pancreas could solve one of the biggest challenges of diabetes | MIT Technology Review (01:02) In a recent trial, a bionic pancreas that automatically delivers insulin proved more effective than pumps or injections at lowering blood glucose levels in people with type 1 diabetes. Type 1 diabetes is a serious condition that causes a person's level of glucose, or sugar, to become too high because the pancreas can't produce enough insulin Needs to be monitored and requires insulin intake every day. But maybe this bionic pancreas, which is a credit card-sized device called an iLet, could alleviate that constant monitoring It monitors a person's levels around the clock and automatically delivers insulin when needed through a tiny cannula, a thin tube inserted into the body.  Worn constantly, generally on the abdomen. Determines all insulin doses based on the user's weight, and the user can't adjust the doses.  A Harvard Medical School team has submitted its findings from the study to the FDA in the hopes of eventually bringing the product to market in the US.  Provided 219 people with type 1 diabetes who had used insulin for at least a year with a bionic pancreas device for 13 weeks.  Compared their blood sugar levels with those of 107 diabetic people who used other insulin delivery methods The blood sugar levels of the bionic pancreas group fell from 7.9% to 7.3%, while the standard care group's levels remained steady at 7.7%.  Goal according to the American Diabetes Association recommends a goal of less than 7.0% Duane Mellor, the lead for nutrition and evidence-based medicine at Aston Medical School, in Birmingham, UK, who was not involved in the study, provided a pro and con for this device: “Being able to take carbohydrate counting out of the equation is a really big advantage, because it's a burden … On the flip side, they have to relinquish control [of determining the insulin dose], which could be difficult for people who've had diabetes for a long time.” The aim of the project is to democratize good glucose control, says Steven Russell, an associate professor of medicine at Harvard Medical School, who led the study: “There are plenty of people who are struggling right now because they don't have the right tools, and I think the iLet could help a lot of them have much better glucose control.” Positive Childhood Experiences of Blue Spaces Linked to Better Adult Well-Being |  Neuroscience News (09:37) A new study on blue spaces from data pulled from the BlueHealth International Survey (BIS) including 18 countries, showcases the benefits 15,000 people across 14 European Countries and 4 other non-European countries/regions Adults with better mental health are more likely to report having spent time playing in and around coastal and inland waters, such as rivers and lakes. Mounting evidence shows that spending time in and around green spaces such as parks and woodlands in adulthood is associated with stress reduction and better mental health. But not much info about blue spaces Respondents between the ages of 0-16 were asked to recall their blue space experiences how local they were,  how often they visited them,  how comfortable their parents/guardians were with them playing in these settings,  They found that individuals who recalled more childhood blue space experiences tended to place greater intrinsic value on natural settings in general, and to visit them more often as adults. Associated to better mental wellbeing in adulthood Valeria Vitale, Lead author and PhD Candidate at Sapienza University of Rome, talks on the findings:  “In the context of an increasingly technological and industrialized world, it's important to understand how childhood nature experiences relate to wellbeing in later life… Our findings suggest that building familiarity and confidence in and around blue spaces during childhood may stimulate an inherent joy of nature and encourage people to seek out recreational nature experiences, with beneficial consequences for adult mental health.” Scientists detect dementia signs as early as nine years ahead of diagnosis | MedicalXpress (15:14) Researchers from the University of Cambridge have shown that it is possible to spot signs of brain impairment in patients as early as nine years before they receive a dementia-related diagnosis. Found impairment in several areas, such as problem solving and number recall The findings raise the possibility that in the future, at-risk patients could be screened to help select those who would benefit from interventions. Maybe reduce their risk of developing one of the conditions, Or could help identify patients suitable for recruitment to clinical trials for new treatments. The issue with treatment for neurological disease is because these conditions are often only diagnosed once symptoms appear, whereas the underlying neurodegeneration may have begun years—even decades—earlier.  May be too late in the disease process to alter its course. UK Biobank collected data from a battery of tests including problem solving, memory, reaction times and grip strength, as well as data on weight loss and gain and on the number of falls. UK Biobank is a biomedical database and research resource containing anonymized genetic, lifestyle and health information from half a million UK participants aged 40-69. Allows for the ability to go back at previous medical history to see if there were signs of neurodegeneration First author Nol Swaddiwudhipong, a junior doctor at the University of Cambridge, said,  "When we looked back at patients' histories, it became clear that they were showing some cognitive impairment several years before their symptoms became obvious enough to prompt a diagnosis. The impairments were often subtle, but across a number of aspects of cognition … This is a step towards us being able to screen people who are at greatest risk—for example, people over 50 or those who have high blood pressure or do not do enough exercise—and intervene at an earlier stage to help them reduce their risk." Offshore wind turbine prototype breaks world record; 359 megawatt-hours within 24 hours | Interesting Engineering (20:10) One of the world's biggest wind turbines has recorded a remarkable renewable energy production total, reining in a massive 359 megawatt-hours within 24 hours. Enough energy to power around 18,000 households yearly Siemens Gamesa, a Spanish-German wind engineering company that manufactures wind turbines for onshore and offshore services, noted that their SG 14-222 DD has broken the record for most power produced by a single turbine in one day. SG 14-222 DD now equals the 14-MW nominal capacity of GE's biggest Haliade-X turbines and only just trailing behind the giant 15-MW Vestas rigs and the world's outright offshore champion, the "monstrous" MingYang 16 MW. The turbine achieved the milestone just ten months after it produced its first electricity and delivered it to the grid at the test center in Østerild, Denmark. Turbine Specs: 14 megawatt (MW) offshore wind turbine with a capacity of up to 15 MW with the "Power Boost" 728 feet (222-meter) diameter rotor  354-feet-long (108-meter-long) B108 blades which can be recycled,  A swept area of 419,792 square feet (39,000 square meters). The company wrote the following on the turbine: “With every new generation of our offshore direct drive turbine technology – which uses fewer moving parts than geared turbines – component improvements have enabled greater performance while maintaining reliability. We are able to reduce the time to market of the SG 14-222 DD thanks to standardized processes and a fully developed supply chain. Enabling high-volume production at low risk. The serial production is planned for 2024.” Stanford exoskeleton breaks out of the lab to offer 30-lb walking boost | New Atlas (29:32) Scientists at Stanford University have been working on an ankle exoskeleton designed to make walking easier. View to one day helping people with impaired mobility  first untethered version for use beyond the lab Their ankle exoskeleton prototype is adjustable in the level of assistance with the max offering a boost akin to taking off a 30-lb (13-kg) backpack. In research published last year, the team demonstrated a version of the device that could increase a wearer's walking speed by around 40%. Previous iterations of the ankle exoskeletons involved complicated laboratory setups with wires, treadmills and external motors. Important for gathering motion data and rapidly testing and fine-tuning the systems to offer the optimal level of assistance The new exoskeleton is a motorized boot that applies torque at the ankle, in doing so performing some of the function of the calf muscle, helping the user push off with each step. Sensors are built into the boot to monitor movement  Uses machine learning algorithms to adapt the level of assistance based on the way the person walks. Takes about an hour of walking for the exoskeleton to become accustomed to the user Team leader Steve Collins, discusses the speed boost they saw: “Optimized assistance allowed people to walk 9% faster with 17% less energy expended per distance traveled, compared to walking in normal shoes … These are the largest improvements in the speed and energy of economy walking of any exoskeleton to date. In direct comparisons on a treadmill, our exoskeleton provides about twice the reduction in effort of previous devices.” The team is now looking to test it out on older adults and disabled subjects, and are also working on versions that improve balance and joint pain. Team member Patrick Slade, on this point said: “I believe that over the next decade we'll see these ideas of personalizing assistance and effective portable exoskeletons help many people overcome mobility challenges or maintain their ability to live active, independent, and meaningful lives.”

Autor: Renata Andrade Lima Revista: NEJM Ref: Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225.

Do COPD medications benefit smokers with significant respiratory symptoms and preserved lung function? Find out about this and more in today's PV Roundup podcast.

We've got an update from Beta Bionics, makers of the iLet pump. This is the system that, among many other things, requires very little input from the user. They're hoping this makes it accessible for more people. Stacey talks to to interim CEO Martha Goldberg Aronson. She shares more information about recent studies regarding the Ilet, news about their submission to the FDA and a look into the future for this long-awaited piece of technology. More about Beta Bionics This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

Joining me for this episode was Mr. Nick Zweig, the Associate Director of Talent Acquisition at Beta Bionics based on Concord, MA. Nick eats and breathes Talent Acquisition. It's by no means just a job for him. He is so passionate and enthusiastic about recruitment and helping companies build high performing teams.Nick has been in recruitment, both on the 3rd party search side as well as being the internal champion for several organizations over the last 16+ years. He has worked for major organizations like Fresenius Medical Care as the Manager of Talent Acquisition for the Manufacturing, Quality, and Supply Chain functions.Currently, he is helping Beta Bionics to scale the organization at rapid pace.Beta Bionics is a MA public benefit corporation, and the team is developing a Bionic Pancreas called the Eyelet which is a fully-integrated medical device that is designed to reduce the burden and costs of Diabetes care by automatically and autonomously managing blood sugar levels 24/7 in people with Type 1 Diabetes.During the show, Nick and I discussed the idea of a "Talent Acquisition Experience"Some highlights covered:-When should "Acquisition of Talent" begin? Hint: Before you have an open position-What Place do Job Descriptions Have in 2021?-Employer Value Proposition vs Performance Profile-What is Employer DNA?-Tactical vs Strategic Talent Acquisition (Brand Awareness)Nick Zweig on LinkedIn:https://www.linkedin.com/in/nickzweig/Beta Bionics on the web:www.betabionics.com

Eoghan Quinn came to my attention a couple of months back. For a couple of reasons. 1)He gained nationwide news coverage as he was attempting to kite surf from France to Ireland (227 miles or 295 nautical miles)2)Like me, he’s a type 1 diabetic and is keen to show the disease can be an enabler, not a disabler. I was delighted to get him onto the podcast to talk about both in detail and a whole lot beside. As you’ll hear, Eoghan is a very focused and motivated guy, keen to keep healthy, fit, not be held back by Type 1 diabetes and even more driven to inspire other Type 1 diabetics to do more and not be held back by limiting beliefsTopics covered:•One of his first memories as he was Diagnosed at the age of 4 and managing the disease ever since •Remembering the panic in his mother’s eyes knowing they were going into a whole new world•No history of type diabetes in the family •Becoming a Coeliac at the age of 5 which added to the complexity •Recalling his first diabetic testing kit •Having a great doctor that supported Eoghan all the way through Primary School •Always being active and leading a full life all the way •Sometimes trying to ignore being a diabetic but changing the mindset and embracing the disease •Dealing with the stigma around being a diabetic and overcoming the shame •The psychological element of being a diabetic •Embracing the technology and having a huge impact once doing this•The Insulin pump being a life changing device •Testing the body and testing the boundaries you can do as a Type 1 diabetic •Realizing that Type 1 Diabetes is not your fault •The impact being of a high glucose, acting fidgety and tired •Turing Type 1 Diabetes into an Enabler •Becoming addicted to challenges to push the limitsoBike Riding from Ireland to Gaza – 180km a day over 5000kmoBike Racing from Melbourne to Sydney in support of Aboriginal healthcare and diabetes•Life expectancy without Insulin & having to pay for insulin in some countries•The challenge of travelling with work as a Type 1 diabetic – the insulin pump works great for this •The preparation into Planning to Kite Surf taking 8 months•As the planning got deeper, the challenge became more and more real•Getting support from Diabetes Ireland and other big brands•Kite Surfing and the challenges of being a Type 1 diabetic •Sending a positive message to other Type 1 diabetics that they can achieve whatever they want •Using the Abbott Free Style Libre and the Insulin Pump to manage his diabetes •Support from Ballycotton Sea Adventures •Working with a Support team who are essential to the success •Setting sail at the end of June but just failing short due to adverse weather conditions •Managing the blood sugars during the challenge and keeping the level between 10 and 11 readings •Planning for everything and controlling everything but the Weather•Arriving into Cork meeting with 60-80 other Type 1 Diabetics and feelings great about the challenge •Raising the awareness for Type 1 Diabetes by doing this challenge •Research into new technology and advances like the bionic pancreases •Learning about the ‘closed-loop’ artificial pancreases creator in the US and looking to get on the clinical trials here•Edward Dimanino motivated to work on a solution after his son was diagnosed with Type 1 Diabetes•Not expecting a cure of T1D ever but looking at technology as a management tool •Huge advances expected in the next 5 years •If you could listen to anyone in a podcast interview – Getting inside the head of a Manager of a Gaelic Football or Hurling Team •Future Challenges & Plans! To Connect with Eoghan and find out more:•Croke Park in November – Event Type 1 Diabetes •Twitter – @EoghanQuinn1 •Instagram - @EoghanQuinn1•LinkedIn - https://www.linkedin.com/in/eoghan-quinn-59b15437/

Eoghan Quinn came to my attention a couple of months back. For a couple of reasons. 1)He gained nationwide news coverage as he was attempting to kite surf from France to Ireland (227 miles or 295 nautical miles)2)Like me, he’s a type 1 diabetic and is keen to show the disease can be an enabler, not a disabler. I was delighted to get him onto the podcast to talk about both in detail and a whole lot beside. As you’ll hear, Eoghan is a very focused and motivated guy, keen to keep healthy, fit, not be held back by Type 1 diabetes and even more driven to inspire other Type 1 diabetics to do more and not be held back by limiting beliefsTopics covered:•One of his first memories as he was Diagnosed at the age of 4 and managing the disease ever since •Remembering the panic in his mother’s eyes knowing they were going into a whole new world•No history of type diabetes in the family •Becoming a Coeliac at the age of 5 which added to the complexity •Recalling his first diabetic testing kit •Having a great doctor that supported Eoghan all the way through Primary School •Always being active and leading a full life all the way •Sometimes trying to ignore being a diabetic but changing the mindset and embracing the disease •Dealing with the stigma around being a diabetic and overcoming the shame •The psychological element of being a diabetic •Embracing the technology and having a huge impact once doing this•The Insulin pump being a life changing device •Testing the body and testing the boundaries you can do as a Type 1 diabetic •Realizing that Type 1 Diabetes is not your fault •The impact being of a high glucose, acting fidgety and tired •Turing Type 1 Diabetes into an Enabler •Becoming addicted to challenges to push the limitsoBike Riding from Ireland to Gaza – 180km a day over 5000kmoBike Racing from Melbourne to Sydney in support of Aboriginal healthcare and diabetes•Life expectancy without Insulin & having to pay for insulin in some countries•The challenge of travelling with work as a Type 1 diabetic – the insulin pump works great for this •The preparation into Planning to Kite Surf taking 8 months•As the planning got deeper, the challenge became more and more real•Getting support from Diabetes Ireland and other big brands•Kite Surfing and the challenges of being a Type 1 diabetic •Sending a positive message to other Type 1 diabetics that they can achieve whatever they want •Using the Abbott Free Style Libre and the Insulin Pump to manage his diabetes •Support from Ballycotton Sea Adventures •Working with a Support team who are essential to the success •Setting sail at the end of June but just failing short due to adverse weather conditions •Managing the blood sugars during the challenge and keeping the level between 10 and 11 readings •Planning for everything and controlling everything but the Weather•Arriving into Cork meeting with 60-80 other Type 1 Diabetics and feelings great about the challenge •Raising the awareness for Type 1 Diabetes by doing this challenge •Research into new technology and advances like the bionic pancreases •Learning about the ‘closed-loop’ artificial pancreases creator in the US and looking to get on the clinical trials here•Edward Dimanino motivated to work on a solution after his son was diagnosed with Type 1 Diabetes•Not expecting a cure of T1D ever but looking at technology as a management tool •Huge advances expected in the next 5 years •If you could listen to anyone in a podcast interview – Getting inside the head of a Manager of a Gaelic Football or Hurling Team •Future Challenges & Plans! To Connect with Eoghan and find out more:•Croke Park in November – Event Type 1 Diabetes •Twitter – @EoghanQuinn1 •Instagram - @EoghanQuinn1•LinkedIn - https://www.linkedin.com/in/eoghan-quinn-59b15437/

SHOW TOPICS: Type I Diabetes, Bionic Pancreas, GMO Bananas, USA Unhealthy, Cannabis (Air Date 6.16.2014) Dr. Rashid A. Buttar hosts "Advanced Medicine" once a week with Robert Scott Bell on the Robert Scott Bell Show. Dealing with everyday health issues from the Advanced Medicine healthcare perspective, Dr. Buttar and Robert tackle the tough issues and empower you to achieve autonomy and maintain your health freedom.

This week, Ed Damiano talks about his Bionic Pancreas project. Using a pump called the iLet and a Dexcom CGM, the only information the Bionic Pancreas needs is the user's body weight. It adapts to you, no need to figure out insulin to carb ratios or correction factors. The iLet will eventually come to market using both insulin and glucagon, but the first version will be insulin-only. Stacey & Ed talk about the long journey to get to this point, why he had to start a brand new kind of company (Beta Bionics) to help bring the iLet to market and just when he expects it to be available. Stacey also shares some of what she learned at the recent HealthEVoices Conference and talks about the milestone of this episode: It's the 100th regularly scheduled show for Diabetes Connections!    

For the 1.25 million American adults and children with type 1 diabetes, managing blood-sugar levels is a 24/7 affair that involves sticking their fingers many times a day and either manually injecting insulin as needed or wearing an insulin pump. Blood glucose management is an inexact science, with levels too high or too low having dangerous consequences. Even a small overdose of insulin can be deadly. Boston University Professor Ed Damiano’s involvement with type 1 diabetes began in May 2000 on a highly personal note when his son David was diagnosed at just 11-months old.

Pepsi’s 3rd quarter was strong thanks to Frito-Lay. TD Ameritrade rises on reports it may buy out rival Scottrade.  And Medtronic gets FDA approval for an artificial pancreas.  Plus we dip into the Fool Mailbag with Bill Mann and Bryan Hinmon from Motley Fool Funds.  Thanks to Pearl Auto for supporting this episode. Go to http://PearlAuto.com/Fool to get free 2-day shipping!

Scott Scolnick was diagnosed with type 1 diabetes more than 40 years ago. He shares his experience living with type 1 as a teen in the 1970s and the emotional moment when he walked his daughter down the aisle, knowing he'd worked so hard to stay healthy for that very special day. Scott was one of the first people to try the Bionic Pancreas. He talks about what it was like to not worry about his blood glucose and how hard it was to go back to "normal" after the trial. Scott now works with Dario and explains its new meter, which connections to a smartphone.

Imagine a social media network where what we say about our lives with diabetes actually drives research. It’s out there, and it’s called Glu. Outreach manager Anna Floreen explains what Glu, and the T1D Exchange are, and how they help researchers focus on what really matters to people living with diabetes and their loved ones. Anna was diagnosed with type 1 at the age of 6. She found great support at camp and recently took part in one of the Bionic Pancreas trials. She tells Stacey how surprised she was at how much of the mental burden of diabetes was lifted, and how difficult it was at the end of the trial to give that up.    

Dr. Ed Damiano is the developer of the bionic pancreas, a closed-loop system that uses a pump and a CGM to automate delivery of insulin as well as glucagon currently in clinical trials. Dr. Damiano got the idea for a dual-chambered system when his son was diagnosed with type 1 at the very young age of 11 months. Dr. Damiano talks to Stacey about the system, now called the "iLet" and about the new company formed to help bring it to market. Called Beta Bionics, it's a unique kind of company, perhaps the first of its kind in the diabetes sector. Dr. Damiano explains what a public benefit corporation is and why he felt it was necessary to form one in order to get the iLet from prototype to commercial product. In this episode, Stacey also shares the story of her family's first JDRF Walk almost ten years ago and how her daughter, who doesn't have diabetes, reacted to the idea of raising money for better research. 

Kelly is a registered nurse and a certified diabetes educator who has been living with type 1 diabetes for 24 years. Recently Kelly completed a six week bionic pancreas trial at Massachusetts General Hospital and she is on the podcast to tell us all about her experience. Hint: It's so cool!   Show Notes Take a moment to learn more about BeyondType1.org, check out their website. Find out more about the bionic pancreas trials at Mass General. Photos from Kelly's trial are on ArdensDay.com and JuicebocPodcast.com Subscribe to the podcast on iTunes today! Check out my type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad The Juicebox Podcast will soon be available on Google Play! Follow Scott on Social Media On Twitter @ArdensDay @JuiceboxPodcast On Facebook Arden's Day - Juicebox Podcast On Instagram @ArdensDay @JuiceboxPodcast Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.

Rob Stein and Rebecca Davis reveal the backstory to their working relationship as reporter and producer.

Last month Wendy Rose took her daughter to a diabetes camp so she could participate in a trial for the Bionic Pancreas. This week Wendy, and her daughter, join me to talk about their experiences. Learn about the Bionic Pancreas, the experience of not caring about type 1 diabetes for a week, and the realization that the future of diabetes technology is upon us. Very exciting times. Enjoy! You can follow Wendy on Twitter @MrsCandyHearts and candyheartsblog.org. And, keep up with the latest information on the Bionic Pancreas at bionicpancreas.com Run Time - 52:45 Send your feedback to feedback@justtalkingpodcast.com.

Originally aired June 20, 2014: Bionic Pancreas in Type 1 Diabetes and Weekly Dalbavancin for Skin Infections Travis and Amol want you to: 1. Understand the potential role of a novel bionic pancreas in glycemic control in type 1 diabetes. 2. Recognize that dalbavancin is non-inferior to vancomycin/linezolid in treating skin infections and represents a potentially revolutionary once ... The post Super Cool Stuff: A Bionic Pancreas and Weekly Antibiotics appeared first on Healthy Debate.

Just a taste of whats coming up. Why isn't Kaiser management showing up for bargaining talks with the California Nurses Association? What are they afraid of? AND, a Bionic Pancreas is coming your way. All this on Nurse Talk @www.nursetalksite.com

A collaborative group from Boston University and Massachusetts General Hospital is working together to make automated blood glucose control a reality, and they have announced their results from the Bionic Pancreas study. Scott, who is also a 20 year+ Type 1 Diabetic on an insulin pump, sits down with Dr. Steven Jon Russell, MD, PhD to talk about this project and it's ramifications.

This week: Bionic Pancreas in Type 1 Diabetes and Weekly Dalbavancin for Skin Infections Travis and Amol want you to: 1. Understand the potential role of a novel bionic pancreas in glycemic control in type 1 diabetes. 2. Recognize that dalbavancin is non-inferior to vancomycin/linezolid in treating skin infections and represents a potentially revolutionary once weekly approach to ... The post Super Cool Stuff: A Bionic Pancreas and Weekly Antibiotics appeared first on Healthy Debate.